==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

Th1034 details
Primary information
ID1246
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionIncreases toxicity of bendamustine. Should not be administered within a 24 hour time period of antineoplastic agent administration.
TargetFibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein
Information of corresponding available drug in the market
Brand NameKepivance
CompanyAmgen Inc
Brand DiscriptionKepivance is a manmade form of a human protein that affects growth of cells within the tissues lining your mouth and digestive tract (esophagus, stomach, and intestines).
Prescribed forKepivance is used to help prevent or heal mouth sores and ulcers in people being treated with chemotherapy and stem cell treatment. It is used in people receiving chemotherapy to treat blood cancers (Hodgkin's disease, multiple myeloma, leukemia).
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceSterile, lyophilized powder
Route of AdministrationIntravenous infusion
Recommended DosageThe recommended dose of Kepivance is 60 mcg/kg/day, administered as an intravenous bolus injection for 3 consecutive days before and 3 consecutive days after myelotoxic therapy, for a total of 6 doses.
ContraindicationN.A.
Side EffectsFever; swelling or redness of your skin; itching or rash; changes in your sense of taste or sense of touch; unusual or unpleasant sensations in your mouth; numbness in or around your mouth; joint pain; or discolored or thickened tongue.
Useful Linkhttp://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110263.htm
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)
Primary information
ID1247
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionIncreases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/drug-interactions/palifermin,kepivance.html
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)
Primary information
ID1248
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/kepivance.html
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)
Primary information
ID1249
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.kepivance.com/patient
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)
Primary information
ID1250
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)
Primary information
ID1251
ThPP IDTh1034
Therapeutic Peptide/Protein NamePalifermin
SequenceSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight16192.7
Chemical FormulaC721H1142N202O204S9
Isoelectric Point9.47
Hydrophobicity-0.65
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionPalifermin(140 residues) is a recombinant human keratinocyte growth factor (KGF) produced using E. coli.
Indication/DiseaseFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
PharmacodynamicsUsed in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Mechanism of ActionKepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesAnti-Mucositis Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25270293, 16179960, 28234746, 28093295, 27942550, 27090960, 27034762, 26968792, 26862696
3-D StructureTh1034 (View) or (Download)